Alice Goodman

Articles

Regorafenib Potential Treatment for Metastatic Colorectal Cancer Failing Standard Treatment Options

March 28th 2012

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

Anastrozole Plus Fulvestrant Improved Survival in Metastatic Hormone Receptor-Positive Breast Cancer

February 13th 2012

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Role of Bisphosphonate Therapy Refined but Still More Questions

February 9th 2012

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

Lenalidomide Plus Docetaxel: Phase III Results Fall Short

February 3rd 2012

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Poorer Outcome in Adults With Localized Ewing Sarcoma Compared With Children

February 1st 2012

Adults with localized Ewing sarcoma have a much lower rate of 5-year survival than do children.

Changing Paradigms for NSCLC in Personalized Therapy Era

January 20th 2012

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Prostate Cancer Armamentarium Expanding

January 20th 2012

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Brain Metastasis Common in Ovarian Cancer

January 20th 2012

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Benefit of ADT Added to Radiation Confined to Intermediate- Risk Prostate Cancer Patients With Poor Prognosis

January 19th 2012

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

SCLC on the Wane, but Difficult to Treat

January 18th 2012

Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.

Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell Carcinoma

January 18th 2012

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

PARP Inhibition Explored in Triple-Negative Breast Cancer

January 16th 2012

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

NKTR 102 Will Move to a Phase III Trial in Pretreated Metastatic Breast Cancer

January 11th 2012

A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.

No Survival Advantage for High-Dose Radiation Versus Standard-Dose Radiation in Stage III NSCLC

January 11th 2012

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.

Radium-223 Properties Conducive to mCRPC Care

December 30th 2011

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

Exploiting Oncogene Addiction and Immunogenicity May Be Path to Improved Results in HER2-Positive Breast Cancer

December 27th 2011

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

Room for Improvement: Reporting Near-Misses and Errors in Radiation Oncology

December 27th 2011

A new study presented at the 2011 annual meeting of the American Society for Radiation Oncology (ASTRO) found that 97% of radiation oncology team members believe they have a responsibility to report near-misses and errors...

Castration-Resistant Prostate Cancer: A Conversation With Cora N. Sternberg, MD

December 16th 2011

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

December 9th 2011

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

December 9th 2011

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.